Skip to main content
SRZN
NASDAQ Life Sciences

Surrozen Reports Massive $242M Net Loss for 2025 Amidst Pipeline Updates and $5M Milestone

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$25.24
Mkt Cap
$216.343M
52W Low
$5.9
52W High
$29.595
52W Position info
328% above low
Off High info
15% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

SRZN has more than doubled off its 52-week low of $5.9.

Summary

Surrozen, Inc. reported a substantial net loss of $242.0 million for the full year 2025, significantly higher than the previous year, alongside a $5 million milestone payment from Boehringer Ingelheim and progress on its lead drug candidates.


Key Events · Earnings and Guidance · SRZN

  • Significant Net Loss Reported

    The company reported a net loss of $242.0 million, or ($32.37) per share, for the full year 2025, a substantial increase from $63.6 million in 2024.

  • Boehringer Ingelheim Milestone Payment

    Surrozen received a $5.0 million milestone payment from Boehringer Ingelheim for SZN-413, following positive IND-enabling toxicology study results.

  • Pipeline Advancement on Track

    The company remains on track to submit an Investigational New Drug (IND) application for its lead candidate, SZN-8141, in the second half of 2026.

  • Cash Position and Recent Financing

    Cash and cash equivalents stood at $89.2 million as of December 31, 2025, supplemented by $26.9 million from at-the-market sales in January 2026 and $3.3 million from warrant exercises in February and March 2026.


Analysis · SRZN · Life Sciences

The reported net loss of $242.0 million for 2025 is extremely large, exceeding the company's current market capitalization, and reflects significant non-cash losses related to a 2025 PIPE and warrant liabilities. While the company secured a $5 million milestone payment and is advancing its SZN-8141 IND application for H2 2026, the dramatic increase in net loss from $63.6 million in 2024 highlights severe financial challenges. Investors should scrutinize the company's cash burn and future financing needs, despite the recent ATM sales and warrant exercises providing some near-term liquidity.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SRZN was trading at $25.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $216.3M. The 52-week trading range was $5.90 to $29.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SRZN - Latest Insights

SRZN
Nov 13, 2026, 8:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $32.05
Real-time Price: $31.88 info
Change: -$0.170 (-0.53%) info
Market Cap: $608.353M info
SRZN
Nov 09, 2026, 4:59 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $32.00
Real-time Price: $31.88 info
Change: -$0.120 (-0.38%) info
Market Cap: $608.353M info
SRZN
Nov 09, 2026, 4:18 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $32.00
Real-time Price: $31.88 info
Change: -$0.120 (-0.38%) info
Market Cap: $608.353M info
SRZN
Nov 09, 2026, 4:06 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $32.00
Real-time Price: $31.88 info
Change: -$0.120 (-0.38%) info
Market Cap: $608.353M info
SRZN
Oct 20, 2026, 4:59 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $25.14
Real-time Price: $31.88 info
Change: +$6.74 (+27%) info
Market Cap: $608.353M info